Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lia Gore

Showing results (71-80 of 119) with videos related to

Pageof 12
Sort By:
Blood Cancer Journal|November 20, 2024
Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomabElias J Jabbour, Hagop M Kantarjian, Nicola Goekbuget, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2010
Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumorsMichael S Gordon, Christopher S Sweeney, David S Mendelson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 23, 2009
Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators' consortiumTanya M Trippett, Cynthia Herzog, James A Whitlock, et al.
Acta Neuropathologica Communications|May 21, 2015
Identification of targets for rational pharmacological therapy in childhood craniopharyngiomaJacob M Gump, Andrew M Donson, Diane K Birks, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2009
Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic studyStephen Leong, Roger B Cohen, Daniel L Gustafson, et al.
Cancer Chemotherapy and Pharmacology|March 18, 2014
A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumorsAmita Patnaik, Patricia M LoRusso, Wells A Messersmith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2016
A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) StudyTodd M Cooper, Jeannette Cassar, Elena Eckroth, et al.
JAMA|March 2, 2021
Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical TrialPatrick A Brown, Lingyun Ji, Xinxin Xu, et al.
The Lancet. Haematology|October 7, 2018
Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 studyFranco Locatelli, Christine Mauz-Koerholz, Kathleen Neville, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2006
A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumorsMichele Basche, Daniel L Gustafson, Scott N Holden, et al.
Pageof 12

Showing results (71-80 of 119) with videos related to

Sort By:
Pageof 12
Blood Cancer Journal|November 20, 2024
Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomabElias J Jabbour, Hagop M Kantarjian, Nicola Goekbuget, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2010
Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumorsMichael S Gordon, Christopher S Sweeney, David S Mendelson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 23, 2009
Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators' consortiumTanya M Trippett, Cynthia Herzog, James A Whitlock, et al.
Acta Neuropathologica Communications|May 21, 2015
Identification of targets for rational pharmacological therapy in childhood craniopharyngiomaJacob M Gump, Andrew M Donson, Diane K Birks, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2009
Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic studyStephen Leong, Roger B Cohen, Daniel L Gustafson, et al.
Cancer Chemotherapy and Pharmacology|March 18, 2014
A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumorsAmita Patnaik, Patricia M LoRusso, Wells A Messersmith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2016
A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) StudyTodd M Cooper, Jeannette Cassar, Elena Eckroth, et al.
JAMA|March 2, 2021
Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical TrialPatrick A Brown, Lingyun Ji, Xinxin Xu, et al.
The Lancet. Haematology|October 7, 2018
Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 studyFranco Locatelli, Christine Mauz-Koerholz, Kathleen Neville, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2006
A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumorsMichele Basche, Daniel L Gustafson, Scott N Holden, et al.
Pageof 12